Svitlana Gumenyuk

Rome, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 32 publications

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.

Nuclear respiratory factor 1 promotes cell survival in multiple myeloma under proteasome inhibition therapy.

Journal: Blood
Published: January 21, 2025

Long-Term Survival with Multiple Myeloma: An Italian Experience.

Long-Term Survival with Multiple Myeloma: An Italian Experience.

Journal: Cancers
Published: December 04, 2024

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

Efficacy and safety of biosimilar Peg-filgrastim after autologous stem cell transplant in myeloma and lymphoma patients: a comparative study with biosimilar Filgrastim, Lenograstim, and originator Peg-filgrastim.

Journal: Annals of hematology
Published: November 17, 2023

Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease.

Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease.

Journal: Leukemia
Published: June 14, 2023

Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.

Prevention of Bortezomib-Induced Peripheral Neuropathy in Newly Multiple Myeloma Patients Using Nervonic Acid, Curcuma Rizoma, and L-Arginine Compound: A Pilot Study.

Journal: Integrative cancer therapies
Published: July 22, 2022

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Myelodysplastic syndromes with del(5q): A real-life study of determinants of long-term outcomes and response to lenalidomide.

Journal: Blood cancer journal
Published: June 22, 2022

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.

Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group.

Journal: EJHaem
Published: October 04, 2021

AATF/Che-1 localizes to paraspeckles and suppresses R-loops accumulation and interferon activation in Multiple Myeloma.

AATF/Che-1 localizes to paraspeckles and suppresses R-loops accumulation and interferon activation in Multiple Myeloma.

Journal: The EMBO journal
Published: September 14, 2021

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.

Impact of anti-CD20 monoclonal antibodies on serologic response to BNT162b2 vaccine in B-cell Non-Hodgkin's lymphomas.

Journal: Leukemia
Published: June 15, 2021

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in multiple myeloma.

Journal: Blood advances
Published: June 04, 2020

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience.

Journal: HemaSphere
Published: May 13, 2020

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?

Journal: Journal of bone oncology
Published: March 31, 2020
Showing 1-12 of 32

Last Updated: 09/26/2026